ArticleFrontiers in veterinary science2025
The kinetic behavior of matrine in pig intestinal lumen after oral administration and its physiologically based pharmacokinetic modeling.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacokinetic Profile of Matrine in Pigs Following Intravenous and Oral Administration.Veterinary sciences · 2026Article
- Matrine as a multi-disease regulator of ferroptosis: mechanisms, therapeutic applications, and toxicity management.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Matrine (MT) has been found to restore the susceptibility of Methods: Two animal experiments were carried out for these purposes. In experiment 1, 12 pigs were implanted with a sterile T-cannula, and then were given a single oral dose of MT or MT-Amoxicillin (AMO) combination at 40 or 70 mg/kg. In experiment 2, 25 pigs were administered with MT at 50 mg/kg/d by oral gavage for 5 d. Intestinal contents were collected at predetermined times and analysed by liquid chromatography tandem mass spectrometry (LC-MS/MS) method. The concentration-time data were analysed by non-compartmental method. Subsequently, a four-compartment PBPK model was developed and validated. Results: After oral administrations, the MT concentrations in pig intestinal lumen increased rapidly and reached their peaks within 2 h, then decreased in a two-phase decay pattern. The co-administered AMO did not alter the kinetic behavior of MT in pig intestinal lumen. The PBPK model gave an accurate prediction of MT concentrations in pig intestinal lumen at most time points. Discussion: A dosage regimen of 70 mg/kg every 8 h was recommended to ensure a sufficient drug exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.